Abstract：Objective To explore the clinical value of dipyridamole combined with standard regimen in the treatment of Kawasaki disease in children. Methods 131 children with Kawasaki disease were prospectively selected.According to the condition of children,different treatment schemes were selected and grouped as follows:Group A(65 cases,treated with immunoglobulin and aspirin)and Group B(66 cases,treated with dipyridamole in addition to immunoglobulin and aspirin).The treatment period was 6-8 weeks.The indexes between groups and within groups were contrasted and analyzed. Results The total effective rate of Group B was higher(compared to Group A),P<0.05.The relief time of various clinical symptoms in Group B was shorter(compared to Group A),P<0.05.The levels of CD8+in peripheral blood increased in both groups(compared to before treatment and after treatment),and Group B was higher(compared to Group A,after treatment);Two groups of peripheral blood CD3+ CD4+、CD4+/CD8+、PLT.The plasma Fbg levels decreased(compared to before treatment and after treatment),and group B had lower levels(compared to group A,after treatment),both P<0.05. Conclusion On the basis of the standard scheme,dipyridamole combined with dipyridamole is effective in treating Kawasaki disease in children.which can effectively alleviate clinical symptoms,improve immune function and coagulation function.
王豪, 何颜祥, 李海啸. 双嘧达莫与标准方案联合治疗儿童川崎病的临床价值[J]. 哈尔滨医药, 2025, 45(4): 46-48.
Wang Hao, He Yanxiang, Li Haixiao. Clinical Value of Dipyridamole Combined with Standard Regimen in the Treatment of Kawasaki Disease in Children. journal1, 2025, 45(4): 46-48.
2025, Vol. 45 
